Stryker has closed its acquisition of Artelon, a privately held company that specializes in soft tissue fixation products for foot & ankle and sports medicine procedures.

Artelon’s synthetic technology was designed to boost biological and mechanical alignment and tendon reconstruction. Its tech has been used in over 60,000 implantations worldwide, according to the company.

The acquisition, which was first revealed last month, allows Stryker to have a more competitive position in the foot/ankle and sports medicine segment with a biomaterial technology that supports healing of soft tissues. It also highlights Stryker’s drive to offer differentiated solutions for reconstructing ligaments and tendons.

“Integrating Artelon’s portfolio into Stryker’s offerings will allow us to deliver best-in-class soft tissue fixation solutions,” said Tim Lanier, president of Stryker’s Trauma & Extremities division. “This acquisition strengthens our competitive edge. Leveraging Artelon’s unique synthetic technology and extensive expertise positions us to continue driving innovation and solidify our leadership in the foot and ankle and sports medicine segments.”

“The acquisition of Artelon will offer enhanced solutions in the soft tissue fixation segment, enhancing our ability to meet the diverse needs of our customers,” added Brent Ladd, president of Stryker’s Endoscopy division. “This is a significant milestone for Stryker as it will provide our customers with advanced technologies designed to improve patient outcomes.”